WO2003089406A1 - Procede de preparation d'un produit intermediaire de cephalosporine et son utilisation pour la fabrication de composes de cephalosporine - Google Patents
Procede de preparation d'un produit intermediaire de cephalosporine et son utilisation pour la fabrication de composes de cephalosporine Download PDFInfo
- Publication number
- WO2003089406A1 WO2003089406A1 PCT/IB2002/004119 IB0204119W WO03089406A1 WO 2003089406 A1 WO2003089406 A1 WO 2003089406A1 IB 0204119 W IB0204119 W IB 0204119W WO 03089406 A1 WO03089406 A1 WO 03089406A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- process according
- methyl
- compound
- chlorine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- -1 cephalosporin compounds Chemical class 0.000 title claims description 13
- 229930186147 Cephalosporin Natural products 0.000 title claims description 11
- 229940124587 cephalosporin Drugs 0.000 title claims description 11
- 150000001780 cephalosporins Chemical class 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 29
- 239000001257 hydrogen Substances 0.000 claims abstract description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 22
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 13
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 13
- 239000000460 chlorine Substances 0.000 claims abstract description 12
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000004913 activation Effects 0.000 claims abstract description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 9
- 150000002367 halogens Chemical group 0.000 claims abstract description 9
- 229910052701 rubidium Inorganic materials 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 52
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 33
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical class CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 16
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Chemical class C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 13
- GWROLNPIZOOAGQ-UHFFFAOYSA-N 2-imino-3-oxobutanoic acid Chemical class CC(=O)C(=N)C(O)=O GWROLNPIZOOAGQ-UHFFFAOYSA-N 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 238000009833 condensation Methods 0.000 claims description 9
- 230000005494 condensation Effects 0.000 claims description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 8
- 230000026030 halogenation Effects 0.000 claims description 8
- 238000005658 halogenation reaction Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 239000001632 sodium acetate Substances 0.000 claims description 7
- 235000017281 sodium acetate Nutrition 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- QITDACOZCQXYQY-BAFYGKSASA-N (6r)-7-amino-5-thia-1-azabicyclo[4.2.0]oct-2-en-8-one Chemical class S1CC=CN2C(=O)C(N)[C@H]21 QITDACOZCQXYQY-BAFYGKSASA-N 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 4
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 150000001983 dialkylethers Chemical class 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 230000002140 halogenating effect Effects 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical group 0.000 claims description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- 229910019213 POCl3 Inorganic materials 0.000 claims description 2
- 229910006124 SOCl2 Inorganic materials 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 238000005580 one pot reaction Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 4
- 239000003242 anti bacterial agent Substances 0.000 abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 description 31
- QWNGESOREPKWTG-UHFFFAOYSA-N 4-chloro-2-methoxyimino-3-oxobutanoic acid Chemical compound CON=C(C(O)=O)C(=O)CCl QWNGESOREPKWTG-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 12
- ZMPDMYFTSINIIZ-QHDYGNBISA-N (6r)-7-amino-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1C(C(N1C=1C(O)=O)=O)N)CC=1CSC(=O)C1=CC=CO1 ZMPDMYFTSINIIZ-QHDYGNBISA-N 0.000 description 10
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- RFLHUYUQCKHUKS-JUODUXDSSA-M Ceftiofur sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 RFLHUYUQCKHUKS-JUODUXDSSA-M 0.000 description 6
- 229960004467 ceftiofur sodium Drugs 0.000 description 6
- 238000006884 silylation reaction Methods 0.000 description 6
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- SIOVKLKJSOKLIF-HJWRWDBZSA-N trimethylsilyl (1z)-n-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N\[Si](C)(C)C SIOVKLKJSOKLIF-HJWRWDBZSA-N 0.000 description 5
- HSHGZXNAXBPPDL-IOJJLOCKSA-N (6r)-3-(acetyloxymethyl)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C(N)[C@@H]12 HSHGZXNAXBPPDL-IOJJLOCKSA-N 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229960004261 cefotaxime Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NGQMPYHAZGBVKN-UHFFFAOYSA-N tert-butyl 2-methoxyimino-3-oxobutanoate Chemical compound CON=C(C(C)=O)C(=O)OC(C)(C)C NGQMPYHAZGBVKN-UHFFFAOYSA-N 0.000 description 2
- 239000005051 trimethylchlorosilane Substances 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- XSPUSVIQHBDITA-KXDGEKGBSA-N (6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CN1N=NC(C)=N1 XSPUSVIQHBDITA-KXDGEKGBSA-N 0.000 description 1
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 description 1
- 229940069744 2,2'-dithiobisbenzothiazole Drugs 0.000 description 1
- HHMCWPVQQZIIFI-SSDOTTSWSA-N CCCC[C@@H](C)OC(C(C(C)=O)=N)=O Chemical compound CCCC[C@@H](C)OC(C(C(C)=O)=N)=O HHMCWPVQQZIIFI-SSDOTTSWSA-N 0.000 description 1
- VOWPVJACXJNHBC-UHFFFAOYSA-N COP(Oc1ccccc1)(Oc1ccccc1)=O Chemical compound COP(Oc1ccccc1)(Oc1ccccc1)=O VOWPVJACXJNHBC-UHFFFAOYSA-N 0.000 description 1
- MWHHJYUHCZWSLS-UHFFFAOYSA-N FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F Chemical compound FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F MWHHJYUHCZWSLS-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960004069 cefditoren Drugs 0.000 description 1
- KMIPKYQIOVAHOP-YLGJWRNMSA-N cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
- 229960004041 cefetamet Drugs 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960003791 cefmenoxime Drugs 0.000 description 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 description 1
- 229960001958 cefodizime Drugs 0.000 description 1
- XDZKBRJLTGRPSS-BGZQYGJUSA-N cefodizime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(C)=C(CC(O)=O)S1 XDZKBRJLTGRPSS-BGZQYGJUSA-N 0.000 description 1
- ZINFAXPQMLDEEJ-GFVOIPPFSA-N cefoselis Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CN1C=CC(=N)N1CCO ZINFAXPQMLDEEJ-GFVOIPPFSA-N 0.000 description 1
- 229950001580 cefoselis Drugs 0.000 description 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 1
- 229960000466 cefpirome Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- 229950009592 cefquinome Drugs 0.000 description 1
- 229950000679 cefteram Drugs 0.000 description 1
- 229960005229 ceftiofur Drugs 0.000 description 1
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960000479 ceftriaxone sodium Drugs 0.000 description 1
- CXHKZHZLDMQGFF-ZSDSSEDPSA-N cefuzonam Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=CN=NS1 CXHKZHZLDMQGFF-ZSDSSEDPSA-N 0.000 description 1
- 229950000807 cefuzonam Drugs 0.000 description 1
- 150000001782 cephems Chemical group 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- AFZSMODLJJCVPP-UHFFFAOYSA-N dibenzothiazol-2-yl disulfide Chemical compound C1=CC=C2SC(SSC=3SC4=CC=CC=C4N=3)=NC2=C1 AFZSMODLJJCVPP-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- WASQWSOJHCZDFK-UHFFFAOYSA-N diketene Chemical compound C=C1CC(=O)O1 WASQWSOJHCZDFK-UHFFFAOYSA-N 0.000 description 1
- LIKFHECYJZWXFJ-UHFFFAOYSA-N dimethyldichlorosilane Chemical compound C[Si](C)(Cl)Cl LIKFHECYJZWXFJ-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 238000006146 oximation reaction Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/14—Esters of phosphoric acids containing P(=O)-halide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/095—Compounds containing the structure P(=O)-O-acyl, P(=O)-O-heteroatom, P(=O)-O-CN
- C07F9/096—Compounds containing the structure P(=O)-O-C(=X)- (X = O, S, Se)
Definitions
- the present invention relates to a process for the preparation of 4-halogeno-2- substituted imino-3-oxo-butyric acid of general formula (I)
- Rt represents CH 3 , CR a R b COOR c where R and R b independently represent hydrogen or methyl and R c represents hydrogen or (C 1 -C 6 )alkyl;
- X represents halogen such as chlorine or bromine.
- the invention also discloses the activation of this acid and its further use in the preparation of cephalosporin antibiotic of formula (II) or its solvates in excellent yields and purity.
- R 3 is carboxylate ion or COOR , where R d represents hydrogen, esters which form a prodrug or a counter ion which forms a salt.
- US patent number 5,095,149 describes a process for the preparation of 4-halogeno- 2- methoxyimino-3-oxo-butyric acid of formula (I) by brominating the methoxy imino compound of general formula (III) by bromine in mixture of D?E and ethylene dichloride.
- Ethylene dichloride is a toxic solvent and hence its use in the preparation of pharmaceuticals has to be avoided.
- EP 0030294 discloses the condensation of the 4- halogeno-2-substituted imino-3-oxo-butyric acid represented by formula (I) with cephem carboxylic acids by using PC1 5 .
- Another EP patent 0 842 937 discloses the formation of amide bond with cephem moiety by reacting with the thioester derivative of 4-chloro-2- methoxyimino-3-oxo-butyric acid.
- the thioester was prepared by reacting 4-chloro-2- methoxyimino-3-oxo-butyric acid with 2,2'-dithio-bis-benzothiazole in the presence of triphenyl phosphine which is a costly material and its by product triphenyl phosphine oxide is also difficult to remove from the reaction mixture.
- the primary objective of the invention is to provide a new process for the preparation of 4-halogeno-2-substituted imino-3-oxo-butyric acid of the general formula (I), which would be suitable for being used in the manufacture of cephalosporin antibiotic, which would be easy to implement in commercial scales.
- Another objective of the present invention is to provide a process for the preparation of 4-halogeno-2-substituted imino-3-oxo-butyric acid of the general formula (I), in good yields with high purity.
- Another objective of the present invention is to carry out the halogenation by photochemical irradiation which would give higher yield and halogenation can also be achieved in presence or absence of solvents thus making the process more environmental friendly.
- Another objective of the present invention is to provide a process for the preparation of cephalosporin antibiotics e.g. cefotaxime, ceftriaxone, cefetamet, ceftiofur, cefditoren, cefpodoxime, ceftadizime, cefepime, cefixime, cefmenoxime, cefodizime, cefoselis, cefquinome, cefpirome, cefteram, cefuzonam etc. which comprises use of 4- halogeno-2-substituted imino-3-oxo-butyric acid of the general formula (I), prepared by the process of the present invention.
- the present invention provides a process for the preparation of 4- halogeno-2-substituted imino-3-oxo-butyric acid of formula (I), which comprises hydrolysis and halogenation of the ester of formula (III) by photochemical irradiation in one pot using a halogenating agent in the absence or presence of a solvent at a temperature in the range of-20°C to 30°C.
- the reaction is as shown in the Scheme-1 below:
- Alk group represents (C ⁇ -C 4 )alkyl group such as methyl, ethyl, n-propyl, iso-propyl, n-butyl or iso- butyl.
- X represents halogen such as chlorine or bromine
- Rt represents CH 3
- R a and R b independently represent hydrogen or methyl and R c represents hydrogen or (C 1 -C 6 )alkyl and X' represents an activating group such as
- Alk group represents (C ⁇ C 4 )alkyl group such as methyl, ethyl, n-propyl, iso-propyl, n-butyl or iso- butyl.
- the solvent used in step (i) is selected from diisopropyl ether, dichloromethane, acetic acid and mixtures thereof.
- the halogenating agent used is chlorine or bromine.
- the light source used for photochemical halogenation is IR or UV radiation, preferably UV radiation.
- the activation in step (ii) is carried out using PC1 5 , DMF/POCl 3 , oxalyl chloride, SOCl 2 /DMF, diphenylchlorophosphoridate, dialkyl chlorophosphoridate, in the presence of a solvent selected from halogenated alkanes, ethyl acetate, tetrahydrofuran, aromatic hydrocarbons, acetone, acetonitrile, dialkylethers or mixtures thereof.
- a solvent selected from halogenated alkanes, ethyl acetate, tetrahydrofuran, aromatic hydrocarbons, acetone, acetonitrile, dialkylethers or mixtures thereof.
- condensation in step (iii) is carried out in the presence of a solvent selected from halogenated alkanes, ethyl acetate, tetrahydrofuran, aromatic hydrocarbons, acetone, acetonitrile, dialkylethers or mixtures thereof.
- a solvent selected from halogenated alkanes, ethyl acetate, tetrahydrofuran, aromatic hydrocarbons, acetone, acetonitrile, dialkylethers or mixtures thereof.
- the cyclisation in step (iv) is carried out using a mixture of water and organic solvent selected from tetrahydrofuran, acetone, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dioxane, (C C 3 )alcohol or mixtures thereof, in the presence of sodium acetate.
- organic solvent selected from tetrahydrofuran, acetone, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dioxane, (C C 3 )alcohol or mixtures thereof, in the presence of sodium acetate.
- the counter ion represented by R d is alkali metal, preferably sodium.
- the compound of formula (I) obtained is a syn-isomer.
- the compound of formula (V), when R represents trimethylsilyl the silylation is carried out by using silylating agent selected from N,O-bis-(trimethylsilyl)acetamide(BSA), hexamethyldisilazane (HMDS) , trimethylchlorosilane (TMCS), dichlorodimethylsilane.
- tert-butyl 2-methoxyimino-3-oxobutyrate 100 gm was dissolved and chlorine gas was introduced into the solution at 0-5°C in the presence of ultraviolet radiation over a period of 18 hours. After completion of the introduction, water (150 ml) was added and then stirred to conduct the water washing to remove the inorganic by-products.
- Step -I Silylation of 7-amino-3-[(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid : Methylene dichloride (100 ml) was charged to the reaction flask followed by addition of 7-amino-3-[(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid (10.0 g) and stirred at room temperature. N, O-bis- (trimethylsilyl) acetamide (BSA) (18.0 g) was added drop wise at room temperature and continued stirring for 2-3 hrs at the same temperature.
- BSA O-bis- (trimethylsilyl) acetamide
- Step -II Activation of 4-chloro-2-methoxyimino-3-oxobutyric acid with PCls Methylene dichloride (60 ml) was charged in the flask followed by addition of 4-chloro-2- methoxyimino-3-oxo-butyric acid (6.3 g) obtained in example 1 or 2 and stirred at - 40°C.
- PC1 5 (7.3g) was added portion wise at -40°C and continued stirring for 1 hr at the same temperature.
- Tetrahydrofuran (150 ml) and water (75 ml) were charged into the reaction flask followed by the addition of condensed product (15.0 g) obtained in step (III) above, thiourea(2.7 g) and sodium acetate (8.0 g). Stirred the reaction mixture at room temperature for 3 hrs. The progress of the reaction was monitored by HPLC. After completion of reaction, sodium chloride (145.0 g) was added to the reaction mixture and stirred at room temperature for 30 min. The tetrahydrofuran layer was separated and was added THF (240 ml), charcoal (5.0 g) stirred for 1 hr at room temperature.
- Step -I Silylation of 7-amino-3-[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-l,2,4-triazin-3- yl)thiomethyl]-3-cephem-4-carboxylic acid : Methylene dichloride (70 ml) was charged to the reaction flask followed by addition of 7- amino-3-[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-l,2,4-triazin-3-yl) thio methyl ]- 3- cephem-4-carboxylic acid (5.0 g, 1.0 mol) and stirred at room temperature.
- Step -III Condensation of activated 4-chloro-2-methoxyimino-3-oxo-butyric acid and silylated 7-amino-3-[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-l,2,4-triazin-3-yl) thiomethyl]-3- cephem-4-carboxylic acid
- Step -II Activation of 4-chloro-2-methoxyimino-3-oxobutyric acid with PCI 5 Methylene dichloride (30 ml) was charged in the flask followed by addition of 4-chloro-2- methoxyimino-3-oxo-butyric acid (7.2 gm, 1.1 mol) obtained in example 1 or 2 and stirred at - 30°C.
- PCI 5 (9.3 gm, 1.1 mol) was added portion wise at -30°C and continued stirring for 1 hr at the same temperature.
- Step -III Condensation of activated 4-chloro-2-methoxyimino-3-oxobutyric acid and silylated 7-amino-3-acetoxymethyl-3-cephem-4-carboxylic acid
- Step-II Activation of 4-chloro-2-methoxyimino-3-oxobutyric acid with DMF/POCI 3
- a suspension of vilsmeir reagent prepared from POCI 3 (3.58 gm,1.4 mol) and DMF (1.71 gm, 1.4 mol) in acetonitrile (24 ml) was added 4-chloro-2-methoxyimino-3-oxo butyric acid (3.0 gm, 1.0 mol) obtained in example 1 or 2 under ice-cooling at 0-5°C.
- the mixture was stirred at the same temperature for 30 minutes.
- Step -III Condensation of activated 4-chloro-2-methoxyimino-3-oxobutyric acid and silylated 7-amino-3-[(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid
- Silylated 7- amino-3-[(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid obtained in step (I) above was added to the activated acid solution obtained in step (II) above at -25°C.
- the separated organic layer was washed with water (75 ml).
- the organic solution was dried and condensed under reduced pressure to give 5.0 gm of the required product.
- Tetrahydrofuran (50 ml) and water (25 ml) were charged into the reaction flask followed by the addition of condensed product (5.0 gm) obtained in step (III) above, thiourea(0.9 gm) and sodium acetate (2.8 gm). Stirred the reaction mixture at room temperature for 3 hrs. The progress of the reaction was monitored by HPLC. After completion of reaction, sodium chloride (48.0 gm) was added to the reaction mixture and stirred at room temperature for 30 min. The tetrahydrofuran layer was separated and was added THF (80 ml), charcoal (0.5 gm) stirred for 1 hr at room temperature.
- Step-I Synthesis of diethyl -(4-chloro-2-methoxyimino-3-oxabutrate) phosphoridate 4-chloro-2-methoxyimino-3-oxobutyric acid (3.0 gm) obtained in example 1 or 2 was suspended in dichloromethane (24 ml) . Triethylamine (0.90 gm) was added into this solution and then diethylchlorophosphoridate (24.52 gm) was also added thereto over 20 minutes while maintaining the solution under nitrogen atmosphere at 0°C to 5°C. The mixture was stirred for 2 hours. After the reaction was completed, distilled water (25 ml) was added to the reaction solution and the mixture was stirred for 5 minutes.
- Step -III Condensation of diethyl-(4-chIoro-2-methoxyimino-3-oxabutrate) phosphoridate and silylated 7-amino-3-[(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid 5
- the suspension of the activated reagent obtained in step (I) above was added to the silylated 7-amino-3-[(2-furanylcarbonyl)thiomethyl]-3-cephem-4-carboxylic acid obtained in step (II) above at -25°C.
- ice-water (25 ml) was added.
- the separated organic layer was washed with water (75 ml).
- the organic solution was dried and condensed under reduced pressure to give 7.5 gm of the required 0 product.
- Tetrahydrofuran (50 ml) and water (25 ml) were charged into the reaction flask followed by the addition of condensed product (5.0 gm) obtained in step (III) above, thiourea (0.9 gm) and sodium acetate (2.8 gm). Stirred the reaction mixture at room temperature for 3 hrs. The progress of the reaction was monitored by HPLC. After completion of reaction, sodium chloride (48.0 gm) was added to the reaction mixture and stirred at room temperature for 30 min. The tetrahydrofuran layer was separated and was added THF (80 ml), charcoal (0.5 gm) stirred for 1 hr at room temperature.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002337437A AU2002337437A1 (en) | 2002-04-19 | 2002-10-08 | A process for the preparation of cephalosporin intermediate and its use for the manufacture of cephalosporin compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN305CH2002 | 2002-04-19 | ||
IN305/MAS/2002 | 2002-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003089406A1 true WO2003089406A1 (fr) | 2003-10-30 |
Family
ID=29227523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/004119 WO2003089406A1 (fr) | 2002-04-19 | 2002-10-08 | Procede de preparation d'un produit intermediaire de cephalosporine et son utilisation pour la fabrication de composes de cephalosporine |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002337437A1 (fr) |
WO (1) | WO2003089406A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005040175A2 (fr) * | 2003-10-22 | 2005-05-06 | Ranbaxy Laboratories Limited | Procede de preparation d'acides carboxyliques de type cephem |
CN102977123A (zh) * | 2012-12-03 | 2013-03-20 | 邓世碧 | 一种头孢类化合物及其药学可接受盐 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0030294A2 (fr) * | 1979-11-21 | 1981-06-17 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Procédé de préparation de dérivés de céphalosporine; intermédiaires et leur préparation |
EP0324418A2 (fr) * | 1988-01-14 | 1989-07-19 | Takeda Chemical Industries, Ltd. | Méthode pour la production de t-butyl-3-oxobutyrates et leur application |
EP0416857A2 (fr) * | 1989-09-04 | 1991-03-13 | Wako Pure Chemical Industries Ltd | Procédé de préparation d'acides gras 4-halogéno-2-alkoximino-3-oxo |
US20020028931A1 (en) * | 2000-08-14 | 2002-03-07 | Ramesh Dandala | Ceftiofur, its intermediate and a process for the preparation of the same |
-
2002
- 2002-10-08 AU AU2002337437A patent/AU2002337437A1/en not_active Abandoned
- 2002-10-08 WO PCT/IB2002/004119 patent/WO2003089406A1/fr not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0030294A2 (fr) * | 1979-11-21 | 1981-06-17 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Procédé de préparation de dérivés de céphalosporine; intermédiaires et leur préparation |
EP0324418A2 (fr) * | 1988-01-14 | 1989-07-19 | Takeda Chemical Industries, Ltd. | Méthode pour la production de t-butyl-3-oxobutyrates et leur application |
EP0416857A2 (fr) * | 1989-09-04 | 1991-03-13 | Wako Pure Chemical Industries Ltd | Procédé de préparation d'acides gras 4-halogéno-2-alkoximino-3-oxo |
US20020028931A1 (en) * | 2000-08-14 | 2002-03-07 | Ramesh Dandala | Ceftiofur, its intermediate and a process for the preparation of the same |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005040175A2 (fr) * | 2003-10-22 | 2005-05-06 | Ranbaxy Laboratories Limited | Procede de preparation d'acides carboxyliques de type cephem |
WO2005040175A3 (fr) * | 2003-10-22 | 2005-07-28 | Ranbaxy Lab Ltd | Procede de preparation d'acides carboxyliques de type cephem |
CN102977123A (zh) * | 2012-12-03 | 2013-03-20 | 邓世碧 | 一种头孢类化合物及其药学可接受盐 |
CN102977123B (zh) * | 2012-12-03 | 2015-04-29 | 邓世碧 | 一种头孢类化合物及其药学可接受盐 |
Also Published As
Publication number | Publication date |
---|---|
AU2002337437A1 (en) | 2003-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6388070B1 (en) | Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds | |
JP2009530268A (ja) | (1−オキサ−又は1−チア−)3−セフェム誘導体及び関連する中間体の調製方法 | |
US7452990B2 (en) | Intermediates for synthesis of cephalosporins and process for preparation of such intermediates | |
US6384215B1 (en) | Preparation of new intermediates and their use in manufacturing of cephalosporin compounds | |
US6919449B2 (en) | Process for the preparation of cephalosporin intermediate and its use for the manufacture of cephalosporin compounds | |
WO2011042776A1 (fr) | Procédé de préparation de l'acide du céfotaxime et de l'un de ses sels pharmaceutiquement acceptables | |
WO1999051607A2 (fr) | Procede de purification d'un derive de cephalosporine | |
JPH05132488A (ja) | 新規セフアロスポリン誘導体 | |
EP1389187A2 (fr) | Procede de preparation d'acide de cefpodoxime | |
US6610845B1 (en) | Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds | |
US20040132995A1 (en) | Process for the preparation of cephalosporins | |
US7511135B2 (en) | Method for manufacture of ceftiofur | |
EP0581220B1 (fr) | Procédé pour la préparation d'intermédiaires de céphalosporine | |
WO2006008749A1 (fr) | Procede de preparation d'intermediaires de cephalosporine pures | |
WO2003089406A1 (fr) | Procede de preparation d'un produit intermediaire de cephalosporine et son utilisation pour la fabrication de composes de cephalosporine | |
WO2008041100A1 (fr) | Procédé amélioré pour la préparation d'antibiotiques céphalosporines | |
WO2004037833A1 (fr) | Procede de preparation d'antibiotiques cephalosporines | |
EP0613480B1 (fr) | Procede de preparation de derives de cephem | |
JPH064641B2 (ja) | セフアロスポリン誘導体の製造方法 | |
US6713625B2 (en) | Process for the preparation of cefditoren using the thioester of thiazolylacetic acid | |
EP1704153A2 (fr) | Procede ameliore pour l'elaboration de sodium de cefotaxime | |
US20060009639A1 (en) | Process for the preparation of cefpodoxime proxetil | |
EP1399429A1 (fr) | 1,3,4-oxadiazol-2-yl thioesters et leur utilisation pour l'acylation de 7-aminocephalosporines | |
WO2004083216A1 (fr) | Procede de preparation de cephalosporines | |
KR20010002705A (ko) | 신규 티아졸 초산의 반응성 포스페이트 유도체의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |